Evidence map›Paper›PMID 31446615›Full record

ArticleMolecular and cellular biochemistry2019

The protective effect of cannabinoid type 2 receptor activation on renal ischemia-reperfusion injury.

Murat Çakır, Suat Tekin, Züleyha Doğanyiğit, Pınar Çakan, Emin Kaymak

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Renoprotective Potential of Nateglinide in an Acute Kidney Injury Model.International journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The effects of cannabinoids on the kidney.Acta physiologica (Oxford, England) · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Expression and Functions of the CBFrontiers in pharmacology · 2022
    Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Murat ÇakırFaculty of Medicine, Department of Physiology, University of Yozgat Bozok, Yozgat, 66200, Turkey. murat.cakir@bozok.edu.tr.ORCID http://orcid.org/0000-0002-2066-829X
Suat TekinFaculty of Medicine, Department of Physiology, University of Inonu, Malatya, Turkey.
Züleyha DoğanyiğitFaculty of Medicine, Department of Histology and Embryology, University of Yozgat Bozok, Yozgat, Turkey.
Pınar ÇakanFaculty of Medicine, Department of Physiology, University of Inonu, Malatya, Turkey.
Emin KaymakFaculty of Medicine, Department of Histology and Embryology, University of Yozgat Bozok, Yozgat, Turkey.
Yozgat Bozok Üniversitesi · TRInonu University · TR

Funding

by Bozok University, Department of Scientific Research Projects 6602b-TF/18-193
6 · The paper itself

Abstract

Kidney ischemia reperfusion (IR) injury is an important health problem resulting in acute renal failure. After IR, the inflammatory and apoptotic process is triggered. The relation of Cannabinoid type 2 (CB2) receptor with inflammatory and apoptotic process has been determined. The CB2 receptor has been shown to be localized in glomeruli and tubules in human and rat kidney. Activation of CB2 receptor with JWH-133 has been shown to reduce apoptosis and inflammation. In this study, it was investigated whether CB2 activation with selective CB2 receptor agonist JWH-133 was protective against renal IR injury. Male Sprague-Dawley rats were divided into 5 groups (n = 45). Bilateral ischemia was treated to the IR group rat's kidneys for 45 min and then reperfusion was performed for 24 h. Three different doses of JWH-133 (0.2, 1 and 5 mg/kg) were administered to the treatment groups at the onset of ischemia. The JWH-133 application at three different doses decreased the glomerular and tubular damage. Additionally, in the renal tissue, nuclear factor-κB, tumour necrosis factor alpha, interleukin-1beta, and caspase-3 levels decreased immunohistochemically. Similarly, JWH-133 application decreased the serum tumour necrosis factor alpha, blood urea nitrogen, creatinine, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, Cystatin C, interleukin-18, interleukin-1beta, interleukin-6, and interleukin-10 levels. We found that JWH-133 and CB2 receptor activation had a curative effect against kidney IR damage. JWH-133 may be a new therapeutic agent in preventing kidney IR damage.

Indexed as

Acute-Phase ProteinsAnimalsBlood Urea NitrogenCannabinoidsCaspase 3CreatinineCystatin CInterleukin-10Interleukin-18Interleukin-1betaInterleukin-6KidneyLipocalin-2LipocalinsMaleNF-kappa B1,1-dimethylbutyl-1-deoxy-Delta(9)-THCAcute-Phase ProteinsCannabinoidsCaspase 3CreatinineCystatin CInterleukin-10Interleukin-18Interleukin-1betaInterleukin-6Lcn2 protein, ratLipocalin-2LipocalinsNF-kappa BProtective AgentsProto-Oncogene ProteinsReceptor, Cannabinoid, CB2Tumor Necrosis Factor-alphaCannabinoid type 2 receptorIschemia–reperfusion injuryJWH-133Kidney

Identifiers

PMID31446615
OpenAlexW2969944132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.